Last reviewed · How we verify

NCT06862388

Stem Cell Therapy for Intracerebral Hemorrhage

Not yet recruiting Phase 1, PHASE2 Last updated 6 March 2025
What this trial tests

Phase 1, PHASE2 trial testing Device: Phase Ⅰ Dose Level 1 in Intracerebral Hemorrhage in 39 participants. Not yet recruiting.

Timeline
1 March 2025
Primary endpoint
28 February 2027
31 July 2027

Quick facts

Lead sponsorTang Zhouping
PhasePhase 1, PHASE2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposetreatment
Enrollment39
Start date1 March 2025
Primary completion28 February 2027
Estimated completion31 July 2027

Drugs / interventions tested

Conditions studied

Sponsor

Tang Zhouping — full company profile →

Who can join

Adults 18 to 65, any sex, with Intracerebral Hemorrhage or Mesenchymal Stem Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intracerebral hemorrhage (ICH) is a common condition with high morbidity, mortality, and disability. The current treatments for ICH primarily include surgical and pharmacological interventions. For large hematomas, surgical options such as craniotomy, debridement, decompression, and minimally invasive hematoma aspiration may be performed. Pharmacological treatments are mainly symptomatic. Despite timely and standardized surgical or pharmacological interventions, many patients with ICH still experience significant sequelae, which severely affect their quality of life and place a substantial burden on both families and society. Currently, there are limited drugs available specifically for the treatment of ICH. In recent years, stem cell therapy has gained attention as a promising treatment for neurological diseases. Human umbilical cord mesenchymal stem cells (UC-MSCs) are multifunctional stem cells with properties such as self-renewal, multidirectional differentiation potential, tissue repair, immunomodulation, and anti-inflammatory effects. Studies have shown that intravenous transplantation of UC-MSCs is safe, and their application in the treatment of ICH can reduce hematoma volume, attenuate cerebral edema and inflammation, and promote the recovery of neurological function. These findings offer a novel therapeutic strategy for ICH. The purpose of this clinical trial is to evaluate the safety and efficacy of UC-MSCs transplantation in patients with subacute intracerebral hemorrhage, and providing a potential new therapeutic approach for this challenging condition.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Clinical Applications of Extracellular Vesicles: Promises and Pitfalls.
    Primorac D, Brlek P, Bulić L, Hrvatin N, et al · · 2026 · cited 1× · PMID 41683929 · DOI 10.3390/ijms27031509

Verify or expand the search:

Other recruiting trials for Intracerebral Hemorrhage

Currently open trials in the same condition.

Other Tang Zhouping trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06862388.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing